Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 7/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223996 | 0.89 | MEN1 (0.47) | ALDH1A1SMN1; SMN2KDM4EMAPTTSHR | |
| SCHEMBL941232 | 0.88 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2KDM4EMAPTTSHR | |
| SCHEMBL939939 | 0.86 | MAPT (0.41) | ALDH1A1SMN1; SMN2KDM4EMAPTTSHR | |
| SCHEMBL940004 | 0.86 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2KDM4EMAPTTSHR | |
| SCHEMBL940176 | 0.81 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2KDM4EMAPTMEN1 | |
| SCHEMBL939815 | 0.77 | ADRA2A (0.44) | ALDH1A1SMN1; SMN2KDM4EMAPTTSHR | |
| SCHEMBL5460979 | 0.77 | ADORA3 (0.46) | ALDH1A1SMN1; SMN2KDM4EMAPTTSHR | |
| SCHEMBL940661 | 0.76 | MAPT (0.45) | ALDH1A1SMN1; SMN2KDM4EMAPTMEN1 | |
| SCHEMBL5224004 | 0.75 | ADORA3 (0.42) | ALDH1A1SMN1; SMN2KDM4EMAPTTSHR | |
| SCHEMBL5462036 | 0.74 | KMT2A (0.48) | ALDH1A1SMN1; SMN2KDM4EMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071601-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2011-12-06 | — | — | US | disclosed |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-7799922-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2010-09-21 | — | — | US | disclosed |
| US-20090247745-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | US | disclosed |
| US-7547696-B2 | Such as 4-methoxy-N-[6-(morpholin-4-yl)-4-benzylamino-3-cyanoquinolin-2-yl]-benzamide; improved solubility | SANOFI-AVENTIS (FR) | 2009-06-16 | — | — | US | disclosed |
| EP-1663982-B1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI AVENTIS (FR) | 2007-11-21 | — | — | EP | disclosed |
| US-20060211689-A1 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS U.S. LLC (US) | 2006-09-21 | — | — | US | disclosed |
| EP-1663982-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | Sanofi-Aventis (FR) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005009969-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211689-A1 | Aminoquinoline derivatives and their use as adenosine A3 ligands | ADORA3, ADORA2A, ADORA1 | ALDH1A1 2526/4885SMN1; SMN2 3694/4885KDM4E 3817/4885 |
| US-20090247745-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA1 | ALDH1A1 2526/4885SMN1; SMN2 3694/4885KDM4E 3817/4885 |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | ALDH1A1 697/4885SMN1; SMN2 4549/4885KDM4E 4274/4885 |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | ALDH1A1 926/4885SMN1; SMN2 4638/4885KDM4E 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.